RT Journal Article
SR Electronic
T1 Cryptococcal Meningitis
JF Practical Neurology
JO Pract Neurol
FD BMJ Publishing Group Ltd
SP 274
OP 285
DO 10.1111/j.1474-7766.2004.00254.x
VO 4
IS 5
A1 Jeremy N Day
YR 2004
UL http://pn.bmj.com/content/4/5/274.abstract
AB INTRODUCTION The HIV pandemic has raised the profile of Cryptococcus neoformans from an obscure yeast to the most important fungal cause of morbidity and death worldwide. Previously described as a rare cause of meningitis in the tropics, or in patients with some form of acquired immunodeficiency such as haematological malignancy or organ transplantation, cryptococcal meningitis is now a significant public health burden in developing countries. 20% of all AIDS deaths are due to cryptococcal meningitis, making it the second most common cause of death in HIV infection after tuberculosis (French et al. 2002). Moreover, despite the availability of highly active antiretroviral therapy (HAART), it continues to pose difficult management questions in the industrialized world. Questions remain for physicians regarding the optimal combination of antifungal agents, duration of treatment, accurate indicators of response to therapy, management of raised intracranial pressure, and the role of adjunctive therapies such as corticosteroids or other